Trials / Recruiting
RecruitingNCT06693440
The Immune Assessment of PD-1 Antibody Therapy in Tumor
The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Quanli Gao · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Detailed description
The primary aim of this study is to evaluate the efficacy and safety of PD(L)-1 antibody therapy for malignant tumors in real-world settings. Treatment outcomes will be assessed according to RECIST V1.1 and iRECIST criteria, with safety graded according to CTCAE V5.0 standards. The study aims to enroll 3000 adult cancer patients treated at this center and analyze their prognosis outcomes based on previous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-1 Inhibitors | Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2027-11-13
- Completion
- 2030-11-13
- First posted
- 2024-11-18
- Last updated
- 2024-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06693440. Inclusion in this directory is not an endorsement.